Seurat Therapeutics

Seurat Therapeutics is based on years of research by Richard Kraig, MD, PhD, at the University of Chicago that targets a naturally-derived cure for migraines aimed at the root cause rather than alleviating the symptoms. Based at the Polsky Center for Entrepreneurship and Innovation’s Polsky Exchange, the team has a vision to give the roughly 4 million people in the US who suffer from migraine their lives back. The migraine treatment is an Insulin-like-growth factor-1 (IGF-1) nasal spray formulation that can relieve migraines within 30 minutes. Seurat Therapeutics licensed their technology through the UCGo! express license program, participated in the Polsky I-Corps program, and was awarded up to $250,000 to support their developments by the George Shultz Innovation Fund. Check out their LinkedIn to stay up-to-date on their efforts in eliminating the ever-pesky migraine.



  • Research conducted by Richard Kraig, MD, PhD
  • Founded in 2016
  • Invested by the George Shultz Innovation Fund (Fall 2016)
  • Finalists at the 2018 Edward L. Kaplan, ’71, New Venture Challenge
  • Headquartered in Chicago, IL

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.